Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Researchers from the Department of Pathology, School of Clinical Medicine at the LKS Faculty of Medicine of the University of ...

Testing and learned that she had a mutation called CDH1. That condition put her at an 80% chance of developing stomach cancer ...

I highly don’t recommend cancer, it’s really not fun. I would rather do 30 colonoscopies in a row than go through freaking ...

A new multicenter study by researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with the National Cancer Institute-funded Clinical Proteomic Tumor Analysis Consortium (CPTAC) ...

She went through testing at the University of Kansas Hospital and learned that she had a mutation called CDH1. That condition ...

Stomach cancer is on the rise in young women under 55 and there is no definitive understanding among scientists of why this ...

T1 Tumor limited to the pancreas and size <2 cm ... cm or invading duodenum or bile duct T4 Tumor invading other organs (stomach, spleen, colon and adrenal gland) or wall of large vessels (celiac ...

which is already approved by the United States Food and Drug Administration to treat gastrointestinal stromal tumors ... Genetic Mutations Linked to Toxin Exposure Found in Firefighters' Brain ...

Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness ...